All In Biotech

Drug Trial Radar · NCT06445062

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,130

Planned (sponsor's estimate)

Start

May 24, 2024

Primary completion

Sep 30, 2028

Study completion Mar 30, 2030

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol G: RMC-9805 + cetuximab + FOLFIRI

Conditions

  • Colorectal Cancer
  • CRC
  • Pancreatic Ductal Adenocarcinoma
  • PDAC
  • Gastrointestinal Cancer
  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • RMC-6236Drug

    Oral tablet

  • mFOLFOX6 regimenDrug

    IV infusion

  • bevacizumabDrug

    IV infusion

  • mFOLFIRINOX regimenDrug

    IV infusion

  • cetuximabDrug

    IV infusion

  • gemcitabineDrug

    IV infusion

  • nab-paclitaxelDrug

    IV infusion

  • RMC-9805Drug

    Oral Tablet

  • FOLFIRI regimenDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (Subprotocols A-F)Time frame: Up to 3 years
  2. Dose limiting toxicities (Subprotocols A-F)Time frame: 28 days
  3. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)Time frame: Up to 3 years

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Chandler, Arizona · Recruiting

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology- Santa Monica

    Los Angeles, California · Recruiting

  • University of Colorado Hospital-Anschutz Cancer Pavilion

    Aurora, Colorado · Recruiting

  • Yale-New Haven Hospital-Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Cancer Center

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • The University of Kansas Clinical Research Center

    Westwood, Kansas · Recruiting

  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Atlantic Health System

    Morristown, New Jersey · Recruiting

  • Northwell Health / RJ Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center Main Campus

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology Dallas

    Irving, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.